VivoSeq
Other

Nasal Polyposis

17

Pipeline Programs↗

4

Active Trials↗

9

Companies Involved↗

Nasal polyposis is an emerging landscape with 17 programs across 9 companies. The most active players are Idorsia Pharmaceuticals Ltd., Glaxo Dba Glaxosmithkline, Validus Pharmaceuticals. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

86/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Idorsia Pharmaceuticals Ltd. logo

Idorsia Pharmaceuticals Ltd.

1 program

Phase 2G

Glaxo Dba Glaxosmithkline

1 program

Phase 2V

Validus Pharmaceuticals

1 program

Phase 2GSK logo

GSK

2 programs

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 3Roche logo

Roche

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

76%

Small molecule

13 of 17 classified programs — the dominant modality here.

24%ALL OTHERSMonoclonal antibody424%

Small molecule leads; the ring shows all 17 classified programs, each share of the total. Modality classified for 100% of 17 pipeline programs.

Analysis

Trial Status

19

clinical trials

Completed12 · 63%
Terminated2 · 11%
Recruiting2 · 11%
Unknown status1 · 5%
Active, not recruiting1 · 5%
Not yet recruiting1 · 5%

Clinical Trials

Trial Activity

19 trials

BIOlogics in Severe Nasal POlyposis SurvEy
Recruiting·UUniversity Hospital, Lille·N/A·NCT05228041·100 enrolled
Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis
Recruiting·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 4·NCT04869436·27 enrolled
Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis
Active, not recruiting·UUniversity of South Florida·Phase 2·NCT04430179·30 enrolled
BIOlogics in Severe Nasal POlyposis SurvEy.: a French Registry
Not yet recruiting·UUniversity Hospital, Lille·N/A·NCT06501807·900 enrolled
Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT03401229·413 enrolled
Double-Blind Randomized Placebo-Controlled Trial on Clinical and Biological Effects of Oral Corticosteroids or Doxycyclin in Patients With Nasal Polyposis
Completed·UUniversity Hospital, Ghent·Phase 2·NCT00480298·48 enrolled
Study to Evaluate Multiple Doses in Patients With Nasal Polyposis
Completed·AAllakos Inc.·Phase 2·NCT02734849·40 enrolled
Mepolizumab in Nasal Polyposis
Completed·GSK logoGSK·Phase 2·NCT01362244·109 enrolled
Mometasone Furoate Nasal Spray for Treatment of Nasal Polyposis After Surgery (Study P03218)
Completed·—·Phase 3·NCT00731185·162 enrolled
Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma
Completed·Novartis logoNovartis·Phase 3·NCT03681093·98 enrolled
An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis
Completed·Sanofi logoSanofi·Phase 2·NCT01920893·60 enrolled
Comparison of Methylprednisolone or Methotrexate in the Maintenance Treatment of Nasal Polyposis
Completed·—·Phase 2·NCT04532736·41 enrolled
Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and Asthma
Completed·UUniversity Hospital, Ghent·Phase 2·NCT01393340·23 enrolled
Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease
Completed·HHead and Neck Surgery Associates·N/A·NCT00215787·20 enrolled
A Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis
Completed·Idorsia Pharmaceuticals Ltd. logoIdorsia Pharmaceuticals Ltd.·Phase 2·NCT03688555·10 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)